Lantheus Medical Imaging, Inc.
331 Treble Cove Road
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Mary Anne Heino
President and Chief Executive Officer
Chief Financial Officer and Treasurer
Senior Vice President, Technical Operations
Senior Vice President - Law and Public Policy, General Counsel and Secretary
Sarah Le Roy
Senior Vice President, Human Resources
Senior Vice President, Corporate Development
Cesare Orlandi, M.D.
Chief Medical Officer
Senior Vice President, Research and Pharmaceutical Development
Senior Vice President, Quality
115 articles with Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging Announces Completion of Exchange Offer for its 9.750% Senior Notes Due 2017
Lantheus Medical Imaging Presents Promising Results of Latest Safety Studies on DEFINITY(R) to FDA Advisory Committees
Lantheus Medical Imaging Announces Expiration of Consent Solicitation and Receipt of Requisite Consents
Lantheus Medical Imaging Receives Special Protocol Assessment Approval from FDA for Phase 3 Trial of Flurpiridaz F-18 for the Diagnosis of Coronary Artery Disease
Lantheus Medical Imaging Announces Completion of Exchange Offer for Its 9.750% Senior Notes Due 2017
Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR(R) and DEFINITY(R)
Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY(R) Supplemental New Drug Application for Use in Stress Echocardiography
Lantheus Medical Imaging Selected to Participate in Premier Healthcare Alliance Comparative Effectiveness Research Program
Lantheus Medical Imaging Announces First Commercial Production of Technelite(R) Generators from Low-Enriched Uranium-Produced Molybdenum-99
Lantheus Medical Imaging to Present Clinical Data on Investigational Cardiac PET Imaging Agents at American Society of Nuclear Cardiology
Lantheus Medical Imaging Commends Safety Labeling Changes Announced by FDA for Gadolinium-Based Contrast Agents
Lantheus Medical Imaging Purchases Balance of Worldwide Rights for MRA Imaging Agent ABLAVAR(R) (Gadofosveset Trisodium)